Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Current Leases: 2020-2024

Historic Current Leases for Apellis Pharmaceuticals (APLS) over the last 5 years, with Dec 2024 value amounting to $6.8 million.

  • Apellis Pharmaceuticals' Current Leases rose 3.39% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year increase of 3.39%. This contributed to the annual value of $6.8 million for FY2024, which is 4.84% up from last year.
  • As of FY2024, Apellis Pharmaceuticals' Current Leases stood at $6.8 million, which was up 4.84% from $6.4 million recorded in FY2023.
  • Over the past 5 years, Apellis Pharmaceuticals' Current Leases peaked at $6.8 million during FY2024, and registered a low of $3.7 million during FY2020.
  • For the 3-year period, Apellis Pharmaceuticals' Current Leases averaged around $6.3 million, with its median value being $6.4 million (2023).
  • Data for Apellis Pharmaceuticals' Current Leases shows a peak YoY skyrocketed of 36.70% (in 2022) over the last 5 years.
  • Apellis Pharmaceuticals' Current Leases (Yearly) stood at $3.7 million in 2020, then increased by 11.67% to $4.1 million in 2021, then surged by 36.70% to $5.6 million in 2022, then rose by 14.51% to $6.4 million in 2023, then increased by 4.84% to $6.8 million in 2024.